Literature DB >> 17240610

Pregnancy in patients of advanced maternal age.

Ferne R Braveman1.   

Abstract

The care of the pregnant patient of AMA is often the care of a high-risk pregnancy. Comorbidities (preexisting or pregnancy-related), combined with high maternal expectation, place these patients at greater need for intervention during pregnancy and parturition. Thirty-eight percent of these patients are treated for preexisting medical conditions and almost half have preexisting medical conditions. Gravidas of AMA are also more likely to develop pregnancy-related illness. Cesarean delivery is more common in older parturients than in women younger than 35 years. Gravidas who have preexisting conditions or who develop illness should be cared for, whenever possible, in a facility capable of managing high-risk pregnancies.

Entities:  

Mesh:

Year:  2006        PMID: 17240610     DOI: 10.1016/j.atc.2006.05.002

Source DB:  PubMed          Journal:  Anesthesiol Clin        ISSN: 1932-2275


  4 in total

Review 1.  Mitochondrial replacement therapy in reproductive medicine.

Authors:  Don P Wolf; Nargiz Mitalipov; Shoukhrat Mitalipov
Journal:  Trends Mol Med       Date:  2014-12-10       Impact factor: 11.951

Review 2.  Surveillance of Hypertension Among Women of Reproductive Age: A Review of Existing Data Sources and Opportunities for Surveillance Before, During, and After Pregnancy.

Authors:  Jonetta J Mpofu; Cheryl L Robbins; Eleanor Garlow; Farah M Chowdhury; Elena Kuklina
Journal:  J Womens Health (Larchmt)       Date:  2021-01-15       Impact factor: 2.681

3.  A review of pregnancy in women over 35 years of age.

Authors:  Reeta Lampinen; Katri Vehviläinen-Julkunen; Päivi Kankkunen
Journal:  Open Nurs J       Date:  2009-08-06

4.  Age, mode of conception, health service use and pregnancy health: a prospective cohort study of Australian women.

Authors:  Jane Fisher; Karen Wynter; Karin Hammarberg; John McBain; Frances Gibson; Jacky Boivin; Catherine McMahon
Journal:  BMC Pregnancy Childbirth       Date:  2013-04-08       Impact factor: 3.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.